# REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

> **NCT07213778** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 2000 (estimated)

## Conditions studied

- Symptomatic Venous Thromboembolism (VTE)

## Interventions

- **DRUG:** REGN7508
- **DRUG:** Acetylsalicylic Acid (ASA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07213778
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2027-05-17
- **Final completion:** 2027-07-16
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213778, "REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07213778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*